Section Arrow
CTXR.NASDAQ
- Citius Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2024/05/16 17:12 EDT
Last
 0.6675
+0.0428 (+6.85%)
Day High 
0.6699 
Prev. Close
0.6247 
1-M High
1.04 
Volume 
989.17K 
Bid
0.6512
Ask
0.66
Day Low
0.62 
Open
0.62 
1-M Low
0.602 
Market Cap 
112.77M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.69 
20-SMA 0.71 
50-SMA 0.77 
52-W High 1.4 
52-W Low 0.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.26/0.02
Enterprise Value
113.04M
Balance Sheet
Book Value Per Share
0.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1001+0.0224+28.83%-- 
DNAGinkgo Bioworks Holdings0.839-0.0001-0.01%-- 
NBYNovaBay Pharmaceuticals0.12+0.0155+14.83%-- 
JAGXJaguar Health0.2867+0.0316+12.39%-- 
NVAXNovavax14.4+1.5+11.63%-- 
Quotes are at least 15-min delayed:2024/05/16 17:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for thetreatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.